Exchange: NASDAQ·Updated 07:30 PM EDT
PTGX logo

PTGX Protagonist Therapeutics Inc

$150.00
$2.72
(1.86%)
Today
Closed $148.80
$1.20
(0.81%)
After Hours
Reported EarningsAug 5
Mkt Cap$9.45B
Vol354,191.00

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
68

Bullish Sentiment

How do you feel about PTGX?

Advertisement|Remove ads.